

C4-2
2
Isotype Control-3
PSMA-3
PSMA
% Cell Viability
120
100
80
60
40
20
0
-12
-11
-10
-9
-8
-7
-6
Log10 [M] Payload

Figure 1A



C4-2
6
Isotype Control-7
PSMA-7
PSMA
% Cell Viability
160
140
120
100
80
60
40
20
0
-11
-10
-9
-8
-7
-6
Log10 [M] Drug

Figure 1B



C4-2
25
Isotype Control-21
PSMA-21
PSMA
% Cell Viability
140
120
100
80
60
40
20
0
-12
-11
-10
-9
-8
-7
-6
Log10 [M] Payload Ig

Figure 1C



PC3/hSTEAP1
6
Isotype Control-7
STEAP1-7
STEAP1
% Cell Viability
120
100
80
60
40
20
0
-12
-11
-10
-9
-8
-7
-6
Log10 [M] Payload

Figure 2



T47D
6
Isotype Control-7
PRLR-7
PRLR
% Cell Viability
120
100
80
60
40
20
0
-11
-10
-9
-8
-7
-6
Log10 [M] Drug

Figure 3



HEK293/hEGFRvIII
6
Isotype Control-7
EGFRvIII-7
EGFRvIII
% Cell Viability
140
120
100
80
60
40
20
0
-11
-10
-9
-8
-7
-6
Log10 [M] Drug

Figure 4



MMT/hEGFRvIII
6
Isotype Control-7
EGFRvIII-7
EGFRvIII
% Cell Viability
140
120
100
80
60
40
20
0
-11
-10
-9
-8
-7
-6
Log10 [M] Drug

Figure 5



U251/hEGFRvIII
6
Isotype Control-7
EGFRvIII-7
EGFRvIII
% Cell Viability
140
120
100
80
60
40
20
0
-11
-10
-9
-8
-7
-6
Log10 [M] Drug

Figure 6



31
6
29
27
HEK293
% Cell Viability
Log10 M Free Drug
A
U87MG
% Cell Viability
Log10 M Free Drug
B

Figure 7



A
HEK293
B
U251
C
C4-2
D
PC3
E
MMT
% Cell Viability
Log10 [M] Payload
9
6
33
35

Figure 8